Celgene partners with Bluebird to develop gene therapies for cancer

03/22/2013 | Genetic Engineering & Biotechnology News

Celgene and Bluebird Bio agreed to collaborate in the discovery, development and marketing of gene therapies for cancer. The collaboration will center on modification of patients' chimeric antigen receptor T cells to target and kill cancer cells. Celgene will pay Bluebird an undisclosed upfront fee and as much as $225 million in option and milestone payments for each product arising from the collaboration.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ